USFDA11 Sept 2026, 05:40 pm
Aurobindo Pharma Subsidiary Unit-IV Clears US FDA Inspection With Zero Observations
AI Summary
Aurobindo Pharma Ltd announced that its wholly owned subsidiary, Apitoria Pharma Private Limited, has successfully completed a US FDA inspection at its Unit-IV API manufacturing facility in Andhra Pradesh. The inspection, conducted from September 7 to September 11, 2026, concluded with zero observations. This positive outcome underscores the company's commitment to maintaining high quality and compliance standards across its manufacturing operations. Aurobindo Pharma will continue to update the stock exchanges on any further developments.
Key Highlights
- US FDA inspection of Apitoria Pharma's Unit-IV completed successfully.
- The inspection concluded with zero observations, indicating strong compliance.
- Unit-IV is an API manufacturing facility, crucial for the company's operations.
- This reinforces Aurobindo Pharma's commitment to quality standards.
Price Impact
More from AUROPHARMA